Charles Ryan, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Charles Ryan, MD

Professor of Clinical Medicine and Urology, Department of Medicine, UCSF
Program Leader, Genitourinary Medical Oncology, UCSF

Thomas Perkins Distinguished Professor in Cancer Research, UCSF

Phone: (415) 353-7171 (appts, urology); (415) 885-3882 (appts, thoracic)
Box 3211, UCSF
San Francisco, CA 94143-3211

View on UCSF Profiles


Additional Websites


Education

Marquette University, BA, 1991, Philosophy
University of Wisconsin - Madison, MD, 1996, Medicine
University of Wisconsin Hospital and Clinics, 1996-97, Intern, Medicine
University of Wisconsin Hospital and Clinics, 1997-99, Resident, Medicine
University of Wisconsin Hospital and Clinics, 1999-00, Chief Resident, Medicine
Memorial Sloan-Kettering Cancer Center, 2000-03, Fellow, Medical Oncology


Professional Experience

  • 2003-2008
    Assistant Clinical Professor of Medicine, UC San Francisco
  • 2008-2014
    Associate Clinical Professor of Medicine, UC San Francisco
  • 2014-present
    Professor of Clinical Medicine and Urology, UC San Francisco

Honors & Awards

  • 1991
    Alpha Sigma Nu, National Jesuit University Academic Honor Society
  • 1991
    Phi Beta Kappa, Marquette University
  • 1994
    Leadership and Service Award, University of Wisconsin Medical School
  • 1996
    John Kimberly Curtis Award, University of Wisconsin Medical School
  • 2000
    Evergreen Award, American College of Physicians-American Society of Internal Medicine
  • 2002
    ASCO Merit Award
  • 2002
    Cancer And Leukemia Group B Young Investigator Award
  • 2006
    Prostate Cancer Foundation: Donald Coffey Career Development Award
  • 2007
    California Coalition to Cure Prostate Cancer Award

Selected Publications

  1. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Kidney cancer, version 3.2015. J Natl Compr Canc Netw. 2015 Feb; 13(2):151-9.
    View on PubMed
  2. Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, Larson SM, Matheny SL, Naini V, Burzykowski T, Griffin TW, Scher HI, Ryan CJ. Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. J Clin Oncol. 2015 Apr 20; 33(12):1356-63.
    View on PubMed
  3. Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD. Clinical cancer advances 2015: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol. 2015 Mar 1; 33(7):786-809.
    View on PubMed
  4. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb; 16(2):152-60.
    View on PubMed
  5. Attard G, de Bono JS, Logothetis CJ, Fizazi K, Mukherjee SD, Joshua AM, Schrijvers D, van den Eertwegh AJ, Li W, Molina A, Griffin TW, Kheoh T, Ricci DS, Zelinsky K, Rathkopf DE, Scher HI, Ryan CJ. Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clin Cancer Res. 2015 Apr 1; 21(7):1621-7.
    View on PubMed
  6. Ryan CJ, Chan JM. Hair, hormones, and high-risk prostate cancer. J Clin Oncol. 2015 Feb 10; 33(5):386-7.
    View on PubMed
  7. Stuyckens K, Saad F, Xu XS, Ryan CJ, Smith MR, Griffin TW, Yu MK, Vermeulen A, Nandy P, Poggesi I. Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2014 Dec; 53(12):1149-60.
    View on PubMed
  8. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76.
    View on PubMed
  9. Kim W, Ryan CJ. Quo vadis: Advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies. Cancer. 2015 Feb 1; 121(3):361-71.
    View on PubMed
  10. Large MM, Ryan CJ. 'Heed not the oracle': risk assessment has no role in preventing suicide in schizophrenia. Acta Psychiatr Scand. 2014 Dec; 130(6):415-7.
    View on PubMed
  11. Ryan CJ, Saylor PJ, Everly JJ, Sartor O. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data. Oncologist. 2014 Oct; 19(10):1012-8.
    View on PubMed
  12. Kim W, Jones JO, Diamond M, Haqq C, Molina A, Small EJ, Ryan CJ. Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):292-9.
    View on PubMed
  13. Montgomery B, Kheoh T, Molina A, Li J, Bellmunt J, Tran N, Loriot Y, Efstathiou E, Ryan CJ, Scher HI, de Bono JS. Impact of Baseline Corticosteroids on Survival and Steroid Androgens in Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis from COU-AA-301. Eur Urol. 2015 May; 67(5):866-73.
    View on PubMed
  14. Hussain M, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, Lee SY, Lin HM, George DJ. Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen. Clin Cancer Res. 2014 Aug 15; 20(16):4218-27.
    View on PubMed
  15. Kim W, Ryan CJ. Friend or foe: the bifunctional role of steroid hormones in prostate cancer. Oncology (Williston Park). 2014 May; 28(5):408, 410.
    View on PubMed
  16. Aggarwal R, Harris A, Formaker C, Small EJ, Molina A, Griffin TW, Ryan CJ. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer. 2014 Oct; 12(5):e167-72.
    View on PubMed
  17. Ryan CJ, Peng W, Kheoh T, Welkowsky E, Haqq CM, Chandler DW, Scher HI, Molina A. Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis. 2014 Jun; 17(2):192-8.
    View on PubMed
  18. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25.
    View on PubMed
  19. Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014 Apr 10; 32(11):1143-50.
    View on PubMed
  20. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R. Kidney cancer, version 2.2014. J Natl Compr Canc Netw. 2014 Feb; 12(2):175-82.
    View on PubMed

Go to UCSF Profiles, powered by CTSI